Apogee Therapeutics (NASDAQ:APGE) Stock Price Up 3.3%

Apogee Therapeutics, Inc. (NASDAQ:APGE)’s share price shot up 3.3% during trading on Friday . The stock traded as high as $55.81 and last traded at $54.68. 120,098 shares were traded during trading, a decline of 76% from the average session volume of 510,036 shares. The stock had previously closed at $52.95.

Apogee Therapeutics Price Performance

The company has a 50-day simple moving average of $47.78 and a 200-day simple moving average of $49.96. The stock has a market cap of $3.30 billion, a PE ratio of -10.64 and a beta of 2.75.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.60). On average, equities analysts expect that Apogee Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other Apogee Therapeutics news, insider Carl Dambkowski sold 5,995 shares of the stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $37.60, for a total value of $225,412.00. Following the completion of the transaction, the insider now owns 294,793 shares in the company, valued at $11,084,216.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Michael Thomas Henderson sold 15,000 shares of the firm’s stock in a transaction on Friday, July 5th. The stock was sold at an average price of $37.26, for a total value of $558,900.00. Following the completion of the transaction, the chief executive officer now owns 1,474,487 shares in the company, valued at $54,939,385.62. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Carl Dambkowski sold 5,995 shares of the firm’s stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $37.60, for a total value of $225,412.00. Following the completion of the transaction, the insider now owns 294,793 shares of the company’s stock, valued at approximately $11,084,216.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 120,995 shares of company stock worth $5,218,774. 36.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Arizona State Retirement System boosted its stake in shares of Apogee Therapeutics by 4.5% during the second quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock valued at $236,000 after acquiring an additional 258 shares during the last quarter. EntryPoint Capital LLC boosted its stake in shares of Apogee Therapeutics by 44.7% during the first quarter. EntryPoint Capital LLC now owns 1,997 shares of the company’s stock valued at $133,000 after acquiring an additional 617 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Apogee Therapeutics by 26.3% during the second quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock valued at $253,000 after acquiring an additional 1,340 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Apogee Therapeutics by 28.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 7,155 shares of the company’s stock valued at $475,000 after acquiring an additional 1,600 shares during the last quarter. Finally, Ameritas Investment Partners Inc. boosted its stake in shares of Apogee Therapeutics by 111.2% during the first quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company’s stock valued at $274,000 after acquiring an additional 2,172 shares during the last quarter. Hedge funds and other institutional investors own 79.04% of the company’s stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.